AMAmit Mittal

Amit Mittal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amit Mittal has a total of 151 co-authors. Here are the top co-authors by number of shared publications:

  • Anuradha Mehra

    Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara (Punjab), 144411, India

    18 shared publications
  • Anu Mittal

    Department of Chemistry, Guru Nanak Dev University College, Patti (Punjab)143416, India

    7 shared publications
  • Gopal Lal Khatik

    National Institute of Pharmaceutical Education and Research

    5 shared publications
  • Rekha Sangwan

    Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara(Punjab) 144411, India

    5 shared publications
  • Shubham Kumar

    Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Jalandhar-Delhi G.T. Road, Punjab, 144411, India

    5 shared publications
  • Anuradha

    Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, Punjab 144411, India

    4 shared publications

Latest Publications

  • Phytochemicals in Alzheimer’s disease: Mechanistic Insights, Targets, and Future Directions

    by Anuradha Mehra, Amit Mittal

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment, cognitive decline, and behavioral alterations. It is the most common form of dementia among older adults and represents a major global health, social, and economic burden. Current pharmacological interventions primarily provide symptomatic relief and have limited efficacy in preventing or reversing the underlying disease pathology, highlighting the need for alternative and innovative therapeutic approaches. Natural compounds with neuroprotective properties have demonstrated considerable potential for targeting multiple pathological mechanisms associated with AD. Phytochemicals, including polyphenols, alkaloids, terpenoids, flavonoids, and other bioactive constituents widely found in fruits, vegetables, herbs, and medicinal plants, exhibit diverse and complementary mechanisms of action. These include inhibition of acetylcholinesterase (AChE), suppression of amyloid-β aggregation, antioxidant and anti-inflammatory activities, and modulation of key signaling pathways involved in neuronal survival and synaptic plasticity. Ginsenosides derived from ginseng, resveratrol from grapes, curcumin from turmeric, and epigallocatechin gallate (EGCG) from green tea are among the most extensively studied phytochemicals and have demonstrated promising neuroprotective effects in numerous preclinical models. These compounds may exert multitarget effects against several pathological hallmarks of AD, offering potential advantages over conventional pharmacological approaches that primarily target individual disease mechanisms. This review provides a comprehensive overview of the therapeutic potential and mechanisms of action of major phytochemicals, with particular emphasis on their prospective applications in the development of novel therapeutic agents and evidence-based preventive strategies for AD.

  • Cholinesterase Inhibitors in Alzheimer's Disease: Medicinal Chemistry, Mechanistic Insights, and Emerging Multitarget Strategies

    by Anuradha Mehra, Rahul Sharma, Amit Mittal

    Alzheimer's disease (AD) is the leading neurodegenerative disorder in the world. Although several decades of research have focused on its multifactorial pathogenesis, treating it remains a great challenge. The approved treatment options include cholinesterase inhibitors (ChEIs), which are the most common symptomatic treatment choice. These drugs act by inhibiting acetylcholinesterase (AChE) and, in some cases, butyrylcholinesterase (BuChE), preventing the breakdown of acetylcholine and increasing cholinergic neurotransmission in the brain. This review provides a broad consideration of ChEIs, focusing on their bioactivity, biochemical action, clinical significance, and SAR trends. It provides a comparative analysis of all the major chemical classes of ChEIs, namely the carbamates and organophosphates, as well as multiple heterocyclic scaffolds, with particular assessment of BBB permeability, metabolic stability, and toxicity attributes. Recent advances in medicinal chemistry have led to a shift in interest toward multi-target-directed ligands (MTDLs) that are designed not only to inhibit ChEs but also to exert antioxidant, anti-inflammatory, anti-amyloid, and metalchelating activity. These can target multiple pathogenic mechanisms to achieve a better therapeutic effect and neuroprotection. This review is based on a robust literature search conducted between 2020 and 2025. The progress, limitations, and prospects of ChEIs in the treatment of AD are critically assessed in this work. It also underscores the need for rational drug design to develop multitargetdirected drugs that may have disease-modifying effects, to overcome the limitations of existing symptomatic cholinesterase-inhibitor monotherapy.

  • SAR and mechanistic pathways of oxadiazole derivatives: targeting enzymes for antidiabetic therapy

    by Anuradha Mehra, Amit Mittal

    Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both (Mehra 2024; Mehra et al. 2024). The g...


  • Polyphenols in Cancer Therapy: Recent Advances, Mechanistic Pathways, and Therapeutic Insights

    by Anuradha Mehra, Amit Mittal

    Polyphenols are naturally occurring compounds characterized by multiple hydroxyl groups attached to aromatic rings. They are broadly classified into four major groups: flavonoids, phenolic acids, lignans, and stilbenes. They act through a number of multiple signalling pathways, including MAPK, PI3K/ Akt, NF-κB, and STAT3 pathways, which induce apoptosis and programmed cancer cell death, which is frequently linked to the development of cancer. Additionally, polyphenols have synergistic effects with chemotherapeutic medications, which makes them attractive options for individual and combination therapy. This review includes studies published between 2019 and 2025 on polyphenols with anti-cancer potential in both in vitro and in vivo analysis. This review integrates recent evidence with a mechanism-based mapping of polyphenol classes to specific anticancer signaling pathways, offering an updated and clinically relevant perspective rarely captured in earlier reviews.


  • Open Access

    Rational Design and Evaluation of Novel TGR5 Agonists for Diabetes

    by Rachana S. Bhimanwar, Zachary Detwiler, Jinge G. Zhu, Samuel T. Saghafi, Carolyn A. Winder, Dawn Belt Davis, Amit Mittal, Vikas Sharma, David A. Harris, Snehal N. Chaudhari

    Agonists of the G protein-coupled receptor TGR5 have long been sought-after for their metabolic benefits. Intestinal TGR5 activation induces secretion of the antidiabetic hormone GLP-1, which can systemically improve diabetes phenotypes in multiple organs. However, no TGR5 agonist drug candidate has succeeded in clinical trials due to their low potency and unwanted side effects. A challenge in the field has been the development of TGR5 agonists that are non-toxic, long-acting, and have functional selectivity for G protein-biased agonism. In this study, we propose a systematic pipeline for engineering optimal TGR5 agonists with antidiabetic properties. This pipeline is interdisciplinary, combining in silico, in vitro, and in vivo assays to design and validate drug candidates. We identify 2 lead compounds that outline the necessary beneficial properties for a successful TGR5 agonist against diabetes. We uncover the molecular mechanisms that allow TGR5 agonists to induce the transcription of their target, TGR5, in intestinal enteroendocrine cells. Lastly, we investigate the molecular interactions of our lead candidates in the TGR5 binding pocket to identify optimal parameters for stability and biological activity. Our strategy for TGR5 agonist design and evaluation has the potential to guide the discovery process for targeted TGR5 therapeutics for metabolic diseases.


  • Decoding the Anticancer Potential of Natural N-Heterocycles: Molecular Frameworks, Bioactivity, and Mechanistic Advances

    by Honey Saini, Anuradha Mehra, Amit Mittal

    Cancer is the leading cause of death and morbidity worldwide. Numerous scientists are trying to develop new anticancer medications that are more potent and less hazardous. This review, in contrast to previous reviews, focuses on the latest research findings from 2020–2025 on N-heterocyclic moieties as natural anticancer agents. This review provides a contemporary evaluation that integrates recent mechanistic discoveries, emerging nanotechnology-based delivery approaches, and translational progress relevant to natural Nheterocyclic anticancer agents. The literature was collected from online sources such as PubMed, Science Direct, Embase, and Google Scholar by searching with keywords like research paper on Natural N-heterocyclic products having anticancer activity, etc. The findings suggest that combining naturally obtained N-heterocyclic compounds with nanotechnology can provide us with a low-toxic anticancer drug in the future. The process of combining natural products containing N-Heterocyclic moieties with nanotechnology can be a game-changer for the development of anticancer medications. Still, there is a lot of research to be done in this area, which can change the viewpoint of the world regarding the treatment of cancer.

  • Targeting EGFR With Indole Derivatives: Recent Advances and Therapeutic Perspectives

    by Tanishq Verma, Anuradha Mehra, Amit Mittal

    Worldwide, cancer is a leading cause of morbidity and mortality. While multiple EGFR inhibitors have emerged, their therapeutic efficacy is constrained by the development of drug resistance and long‐term toxicity. Indoles have been identified as one of the promising scaffold classes to compete against EGFR in terms of selectivity and potency. They are favorable for anticancer drug discovery because they are structurally plastic, possess favorable pharmacokinetics, and bind to the ATP‐binding pocket of EGFR. Indole derivatives inhibit the auto‐phosphorylation of EGFR, thereby exhibiting their activity against cancers by blocking cancer cell proliferation, survival, and metastasis. The translation potential of this scaffold is also supported by the clinical success of indole‐based EGFR inhibitors, including the third‐generation drug osimertinib. Recent advances in molecular docking, structure–activity relationship studies, and hybrid drug design highlight the potential of indole‐based scaffolds to address resistance mutations while minimizing side effects. This paper summarizes the relevant literature of indole EGFR inhibitors published between 2021 and 2025, which may include mechanistic insights, biological screening, and therapeutic potential. The indole scaffold can be a useful starting point to push forward the next generation of targeted cancer therapies.


  • Metabolic and Pharmacokinetic Perspectives on Hepatotoxic Agents in Experimental Cirrhosis

    by Anuradha Mehra, Roopal Mittal, Amit Mittal, Rekha Sangwan, Tanmoy Roy, Anu Mittal, Neha Raj, Ruchi Kohli

    Cirrhosis is a very serious, gradual liver disease characterized by the overproduction of collagen and scarring, which together may result in liver failure or hepatocellular cancer. It typically develops based on fibrosis, which may be reversible when diagnosed in its initial stages. Viral hepatitis, alcohol, non-alcoholic fatty liver disease, and drug-induced hepatotoxicity are some of the etiologies of the disease. It is worth noting that about half of the cases of hepatic damage in patients are known to be caused by drug-induced liver injury. The existence of the pathophysiological complexity and therapeutic reactions of cirrhosis requires experimental models that are reliable. This review gives insight into the different in vivo, ex vivo, and operative animal models employed to cause hepatic injury by application of chemicals, drugs, dietary, and bile duct ligation particulars. The focus is on the mechanistic understanding of the actions of hepatotoxic substances, their involvement in oxidative stress, mitochondrial pathology, and the inflammatory process. Each model is critically discussed in terms of its advantages, limitations, and translational relevance.Additionally, this work highlights emerging alternatives, such as organ-on-a-chip systems, 3D co-cultures, and hepatic bioengineered tissues, as solutions that aim to reduce animal use and increase physiological relevance. The review also discusses biomarkers, histopathological endpoints, and important molecular players in hepatic fibrosis and cirrhosis. The review also examines data from preclinical studies of hepatoprotective substances and modulators of fibrosis, as it facilitates the integration of data from various experimental platforms. The next steps involve personalized pathology based on decellularized liver scaffolding and patient cells, aiming to better determine clinical outcomes and treatment responses.


  • Design, Synthesis, and Evaluation of New Dienones as Antifungal Agents

    by Anuradha Mehra, Rekha Sangwan, Amit Mittal

    The growing resistance of fungi to antifungal drugs has become a matter of concern for public health in the last few years. The pursuit requirement for innovative therapeutic motifs is still crucial toward many new pathosis and resistant strains of microorganisms. Chalcones are ketones α, β‐unsaturated which further designed with extended conjugation of double bonds were synthesized and screened for anti‐fungal pathogens lifted with molecular docking study. The structural verification of all the compounds was performed using NMR, and ADMET and physicochemical profiling were used to analyze them. The 3d and 4d molecules are promising lead molecules, which are supported by both computational and in vitro data. The study determined that novel synthesized dienones enhanced anti‐fungal activity both in vitro and in a computational study. The in silico designing and docking analysis results were found to comply with the in‐vitro result.

  • Inclusive Drug Designing of Novel Indole Derivatives using Rationale, Pharmacophore Mapping and Molecular Docking

    by Anuradha Mehra, Amit Mittal, Rahul Sharma, Rekha Sangwan, Aryan Mehra

    Background: The presence of insufficient insulin signaling in type 2 diabetes arises due to either insulin resistance or impaired insulin secretion, ultimately leading to elevated blood glucose levels, a condition known as hyperglycemia. Diabetes poses a pervasive worldwide challenge, with its prevalence steadily surging in both developed and developing nations. A promising avenue for improving the management of diabetes type 2 involves the exploration of glucokinase activators as an innovative therapeutic target. Notably, a recent breakthrough in this area has been the market approval granted by the Japanese FDA for the use of the innovative GKA, Dorzagliatin, in the treatment of diabetes type 2. Objective: To augment the management of diabetes type 2 and mitigate the undesirable side effects linked to prolonged use of conventional medications, this research endeavor sought to create innovative glucokinase activators. Methods: The ZINC database yielded a collection of 56 compounds, each showcasing a 40% structural similarity to 1-(phenylsulfonyl)-1H-indole-2-carboxylic acid. These compounds, all featuring the distinctive indole core, were meticulously selected for further investigation. Structural illustrations were crafted using ChemBioDraw Ultra, and 1.5.6 AutoDock Vina was for molecular docking. The Swiss ADME algorithm facilitated online log P predictions, while the software PKCSM was utilized to forecast the toxicity profiles of the leading compounds. DFT analysis was done to ensure the stability of compounds by using Gaussian 16 quantum chemistry software and Mulliken charge distributions used to optimize molecular geometries. Results: Among all the compounds, RS33 and RS37 exhibited the highest affinities for GK receptors, with the docking scores of -8.93 and -8.44 kcal/mol, respectively. These compounds follow Lipinski’s Rule, indicating promising absorption and excretion profiles through the gastrointestinal tract. Compared to standard drugs Dorzagliatin (GKA) and MRK (co-crystallized ligand), both RS33 and RS37 demonstrate no AMES toxicity, skin sensitization, and hepatotoxicity. RS43 is the most stable compound as it has high ΔE, η, and χ in DFT analysis. Conclusion: The novel-designed lead molecules demonstrate an enhanced pharmacokinetic profile, superior binding affinity, and minimal toxicity, based on computational study. These attributes make them promising candidates for further optimization as glucokinase activators.